|
|
Browse products Anticancer agents in preclinical trials Anticancer molecular libraries Other drug agents
|
MedKoo product information:
BIX02188
Description of BIX02188: BIX02188 is a MEK5 inhibitor which inhibits catalytic function of purified, MEK5 enzyme. The MEK5 inhibitor blocked phosphorylation of ERK5, without affecting phosphorylation of ERK1/2 in sorbitol-stimulated HeLa cells. BIX02188 also inhibited transcriptional activation of MEF2C, a downstream substrate of the MEK5/ERK5 signaling cascade, in a cellular trans-reporter assay system. These inhibitors offer novel pharmacological tools to better characterize the role of the MEK5/ERK5 pathway in various biological systems. (source: Biochem Biophys Res Commun. 2008 Dec 5;377(1):120-5. Epub 2008 Oct 1.).
Current developer: Boehringer Ingelheim Pharmaceuticals, Inc.
BIX02188 is a novel MEK5 inhibitor, which inhibited catalytic function of purified, MEK5 enzyme. The MEK5 inhibitors blocked phosphorylation of ERK5, without affecting phosphorylation of ERK1/2 in sorbitol-stimulated HeLa cells. The compds. also inhibited transcriptional activation of MEF2C, a downstream substrate of the MEK5/ERK5 signaling cascade, in a cellular trans-reporter assay system. This inhibitors offer novel pharmacol. tools to better characterize the role of the MEK5/ERK5 pathway in various biol. systems.
1: Obara Y, Nakahata N. The signaling pathway leading
to extracellular signal-regulated kinase 5 (ERK5) activation via
G-proteins and ERK5-dependent neurotrophic effects. Mol Pharmacol. 2010
Jan;77(1):10-6. Epub 2009 Oct 26. Review. PubMed PMID: 19858097. |
Contact MedKoo: Email: sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
||||||||||||||
About us | Services | Products | News | Careers | Contact us